Prot#AL001-3: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene

Project: Research project

Project Details

Effective start/end date11/12/2011/12/23


  • PPD Investigator Services, LLC (Prot# AL001-3 // Prot# AL001-3)
  • Alector, Inc. (Prot# AL001-3 // Prot# AL001-3)